Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13192978 | 0.98 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL8475968 | 0.98 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL8481728 | 0.98 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL8465977 | 0.95 | NR1H2 (0.31) | NR1H2NR1H3 | |
| SCHEMBL13192467 | 0.90 | ACLY (0.37) | — | |
| SCHEMBL8482393 | 0.84 | SIGMAR1 (0.33) | SIGMAR1NR1H2NR1H3 | |
| SCHEMBL8136342 | 0.84 | GAA (0.39) | SIGMAR1 | |
| SCHEMBL2631387 | 0.83 | KCNH3 (0.33) | SIGMAR1NR1H2NR1H3 | |
| SCHEMBL18215221 | 0.83 | GAA (0.38) | SIGMAR1 | |
| SCHEMBL15686603 | 0.83 | KCNH3 (0.33) | SIGMAR1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245508-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-09-27 | — | — | US | disclosed |
| US-8207329-B2 | Synthesis of chlorins and phorbines with enhanced red spectral features | NORTH CAROLINA STATE UNIVERSITY (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090227553-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-10 | — | — | US | disclosed |
| WO-2008080988-A2 | CYCLOPENTANONE DERIVATIVES, METHOD OF SYNTHESIS AND USES THEREOF | NEUROPHARMA, S.A. (ES) | 2008-07-10 | — | — | WO | disclosed |
| EP-1939192-A1 | Cyclopentanone derivatives, method of synthesis and uses thereof | Neuropharma S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227553-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | CRY1, CRY2, HCCS | SIGMAR1 3439/4885NR1H2 1657/4885NR1H3 1909/4885 |
| US-20120245508-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | CRY1, CRY2, QDPR | SIGMAR1 3506/4885NR1H2 1710/4885NR1H3 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.